Luise Rupp, Ina Dietsche, Maximilian Kießler, Ulrich Sommer, Alexander Muckenhuber, Katja Steiger, Casper W F van Eijck, Leonard Richter, Rouzanna Istvanffy, Carsten Jäger, Helmut Friess, Casper H J van Eijck, Ihsan Ekin Demir, Carmen Mota Reyes, Marc Schmitz
Pancreatic ductal adenocarcinoma (PDAC) is typically diagnosed at advanced stages and associated with early distant metastasis and poor survival. Besides clinical factors, the tumor microenvironment (TME) emerged as a crucial determinant of patient survival and therapy response in many tumors, including PDAC. Thus, the presence of tumor-infiltrating lymphocytes and the formation of tertiary lymphoid structures (TLS) is associated with longer survival in PDAC. Although neoadjuvant therapy (NeoTx) has improved the management of locally advanced tumors, detailed insight into its effect on various TME components is limited...
2024: Frontiers in Immunology